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Next-generation sequencing in thyroid 
cancer
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Abstract 
Next-generation sequencing (NGS) in thyroid cancer allows for simultaneous high-throughput sequencing analysis 
of variable genetic alterations and provides a comprehensive understanding of tumor biology. In thyroid cancer, 
NGS offers diagnostic improvements for fine needle aspiration (FNA) cytology of thyroid with indeterminate features. 
It also contributes to patient management, providing risk stratification of patients based on the risk of malignancy. 
Furthermore, NGS has been adopted in cancer research. It is used in molecular tumor classification, and molecular 
prediction of recurrence and metastasis in papillary thyroid carcinoma. This review covers previous NGS analyses 
in variable types of thyroid cancer, where samples including FNA cytology, fresh frozen tissue, and formalin-fixed, 
paraffin-embedded tissues were used. This review also focuses on the clinical and research implications of using NGS 
to study and treat thyroid cancer.
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Background
An understanding of the molecular mechanisms of tumor 
formation is mandatory for accurate diagnoses and per-
sonalized treatments. Previously, single gene assays were 
commonly used for finding molecular alterations in 
tumors. Presently, NGS technology provides the simulta-
neous analysis of hundreds of genes of interest, using tar-
geted sequencing panels [1]. Thus, NGS-based molecular 
tests for oncology research and clinical practice appear to 
be rapidly evolving.
Thyroid cancer is the most common malignancy of the 
endocrine organs; its prevalence is increasing, more than 
tripling during the last three decades [2]. Papillary thy-
roid carcinoma (PTC) is the most common type of thy-
roid cancer, followed by follicular carcinoma, medullary 
carcinoma, poorly differentiated carcinoma, and anaplas-
tic carcinoma. NGS assays can allow improvements in 
diagnostic accuracy and precise personalized treatments. 
Thyroid cancers harbor characteristic genetic alterations, 
including point mutations for proto-oncogenes (BRAF, 
NRAS, HRAS, KRAS) and chromosomal rearrangements 
(RET/PTC1, RET/PTC3, PAX8/PPARG), which vary with 
histologic subtype [3]. This review outlines the results of 
NGS assays in thyroid cancer, and highlights their clinical 
implications.
NGS application in the diagnosis of indeterminate 
cytology
A majority of previous studies using NGS in thyroid can-
cer analyzed variable specimen sample types and histo-
logic subtypes (Table 1). In clinical practice, NGS assays 
have been used in the diagnosis of indeterminate cytol-
ogy of thyroid nodules. FNA is an efficient method for 
evaluating thyroid nodules that has high sensitivity and 
specificity. However, FNA has some limitations, since 
20–30% of FNA samples fall into categories of indeter-
minate cytology. These categories include atypia of unde-
termined significance/follicular lesion of undetermined 
significance (AUS/FLUS, category III); follicular or onco-
cytic (Hurthle cell) neoplasm/suspicious for a follicular 
or oncocytic (Hurthle cell) neoplasm (FN/SFN, category 
IV); and suspicious for malignant cells (SUSP) [4–8]. The 
average cancer risk for these categories is 15.9% in AUS/
FLUS, 26.1% in FN/SFN, and 75.2% in SUSP [9]. NGS 
contributes to diagnostic decision making in patients 
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studies, which used NGS to analyze thyroid nodules with 
indeterminate cytology, are summarized in Table 2.
Genetic alteration of thyroid cancer and NGS
Papillary carcinoma
Several studies have applied NGS to variable subgroups 
of PTCs. Nikiforova et al. analyzed FFPE or frozen tissue 
from 27 classic PTCs and 30 FVPTCs, using the ThyroSeq 
NGS panel targeting 12 genes with 34 amplicons on the 
Ion Torrent PGM sequencer [10]. The results showed 
that 70% of classic PTCs harbored mutated genes: BRAF 
(59%) was the most frequent, followed by PIK3A (11%), 
TP53 (7%), and NRAS (4%). In contrast, 83% of FVPTCs 
had mutated genes: RAS (73%) was the most frequent, 
followed by BRAF (7%) and TSHR (3%) [10]. Smallridge 
et  al. performed RNA sequencing (RNA-Seq) using the 
Illumina HiSeq 2000 platform on frozen tissue from 12 
BRAF V600E-mutated PTCs and 8 BRAF-wild type PTCs 
[11]. Among the 13,085 genes interrogated, 560 were 
differentially expressed between BRAF V600E-mutated 
PTCs and BRAF-wild type PTCs [11]. Among these 560 
genes, 67 were related to immune function pathways, 51 
were under-expressed in BRAF V600E-mutated PTCs, 
and HLAG, CXCL14, TIMP1, and IL1RAP were over-
expressed. In BRAF-wild type PTCs, 4 immune function 
genes (IL1B, CCL19, CCL21, and CXCR4) were most sig-
nificantly differentially expressed, and exhibited a high 
degree of correlation with lymphocytic infiltration [11]. 
In a study by Leeman-Neill et al. fresh frozen tissue from 
62 radiation-associated PTCs and 151 sporadic PTCs 
was analyzed using RNA-Seq on the Illumina HiSeq 2000 
platform. This identified an ETV6-NTRK3 rearrange-
ment in 14.5% of radiation-associated PTCs and 2% of 
sporadic PTCs [12]. The authors suggested that an ETV6-
NTRK3 rearrangement may be a key mechanism of radi-
ation-induced carcinogenesis [12].
The Cancer Genome Atlas (TCGA) Network described 
the genomic characterization of 496 PTCs, and gener-
ated data using whole genome sequencing. This was done 
on the NGS platform and by a multiplatform analysis of 
SNP arrays, DNA methylation, and reverse phase pro-
tein arrays [13]. In PTCs that lacked known driver muta-
tions, alterations of EIF1AX, PPMID, and CHEK2 were 
discovered as potential new tumor-initiating mutations. 
The TCGA project identified the TERT promoter muta-
tion, which accounts for approximately 1% of PTCs, but 
shows association with a high risk of recurrence. Based 
on the multi-level molecular data, PTCs were sepa-
rated into two groups of distinct downstream signaling 
pathways: the BRAFV600E-like cohort and the RAS-like 
cohort. Genomic, epigenomic, and proteomic differences 
were revealed between these two groups, and most of the 
RAS-like PTCs were follicular variant PTCs (FVPTCs).
Regarding pediatric thyroid carcinoma, Picarsic et  al. 
analyzed 17 pediatric PTCs (age range 8–17  years, 
median 13  years) from FNA, fresh frozen tissue, and 
FFPE samples. Mutation analysis with a 7-gene mutation 
panel using real-time PCR and ThyroSeq v2 on the Ion 
Torrent PGM sequencer showed that: (1) The detection 
rate of molecular alterations was increased by up to 87% 
by the ThyroSeq v2 NGS assay compared to an increase 
of 60% by the 7-gene mutation panel. (2) In pediatric 
thyroid carcinoma, chromosomal rearrangement (53%) 
was more common than point mutation (33%). (3) ETV6-
NTRK3 fusion was identified in 18% of samples, and 
was associated with aggressive histologic features such 
as non-encapsulation, solid/insular/trabecular patterns, 
extensive glandular involvement, and thick tumor fibro-
sis [14]. Ballester et al. analyzed FFPE and FNA samples 
from 25 pediatric PTCs (age range 10–19 years, median 
14  years) using the 50-gene Ion AmpliSeq Cancer Hot-
spot Panel v2 on the Ion Torrent PGM sequencer [15]. 
No additional mutations were detected using the NGS 
assay on pediatric PTCs that initially were negative for 
BRAF V600E mutation, RET/PTC1/3 fusion, and TERT 
promoter mutation [15].
Follicular carcinoma
Follicular carcinoma (FC) is a well-differentiated thyroid 
carcinoma and the second-most common thyroid cancer 
after PTC. It accounts for 10% of the total thyroid cancers 
[16]. Although it is not firmly established, FC is classified 
into the minimally invasive type and the widely invasive 
type, according to the microscopic tumor extent [17]. It 
can be classified into the conventional type and the onco-
cytic type (Hurthle cell type) on the basis of cell type [18].
A previous study retrospectively collected FFPE or 
fresh frozen tissue samples from 36 FCs to study 12 can-
cer genes and 34 amplicons using the ThyroSeq panel on 
the Ion Torrent PGM sequencer. The analysis detected 
mutations of NRAS (N  =  9), KRAS (N  =  2), HRAS 
(N = 1), TSHR (N = 4), TP53 (N = 4), and PTEN (N = 1) 
[10]. Interestingly, conventional type (N  =  18) and 
oncocytic type (N  =  18) samples showed distinguished 
genetic alterations. In the conventional type FCs, NRAS 
was the most frequently affected gene, followed by TSHR 
and KRAS. TP53 was the most commonly mutated gene 
in the oncocytic type FCs, followed by HRAS, KRAS, and 
PTEN [19].
Swierniak et  al. analyzed 26 follicular adenomas, 22 
FCs, and 34 paired normal thyroid tissue samples. Tar-
geted NGS of 372 genes using the TruSeq kit on the Illu-
mina HiSeq  1500 platform yielded the following results 
[20]: (1) Somatic alterations were identified in oncogenes 
(MDM2, FLI1), transcription factors and repressors 
(MITF, FLI1, ZNF331), epigenetic enzymes (KMT2A, 
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NSD1, NCOA1, NCOA2), and protein kinases (JAK3, 
CHEK2, ALK). (2) Single nucleotide variants were the 
most common types of mutations, and large structural 
variants were the least frequent. (3) A novel transloca-
tion in DERL/COX6C was detected. (4) Somatic altera-
tion affected non-coding gene regions and exhibited high 
penetrance. These results suggest that FC has significant 
molecular heterogeneity, since FC reveals far more com-
plex somatic alterations than PTC, and each tumor har-
bors distinct somatic alterations.
Poorly differentiated carcinoma and anaplastic carcinoma
Poorly differentiated carcinoma (PDC) and anaplastic 
carcinoma (AC) are rare types of thyroid carcinoma, each 
with a prevalence of 10% [21, 22], and a 1–2% among all 
thyroid carcinomas [23]. PDC and AC have poor prog-
noses, with a 5-year survival rate of 51% and 0%, respec-
tively [24]. Since these types of cancers respond poorly 
to conventional treatment options (including radioio-
dine therapy, chemotherapy, and radiotherapy), there 
are already clinical trials for molecular-targeted agents 
underway [25, 26]. Using NGS, it may be possible to 
identify targetable gene alterations that can improve the 
course of patient treatment.
In a study using the ThyroSeq panel on the Ion Tor-
rent PGM sequencer, 12 genes with 34 amplicons were 
analyzed from FFPE or fresh frozen tissue from 10 PDCs 
and 27 ACs. The study showed that 30% of PDCs had 
mutations, whereas 74% of ACs had mutations [10]. The 
altered genes were NRAS, PIK3CA, GNAS, and BRAF 
in PDCs, and TP53, BRAF, RAS, PIK3CA, PTEN, and 
CTNNB1 in ACs.
Sykorova et  al. analyzed fresh frozen tissue samples 
from 3 PDCs and 5 ACs using the TruSight Cancer Panel, 
targeting 94 cancer-related genes on the Illumina MiSeq 
sequencer [27]. All PDCs and ACs showed more than one 
genetic alteration, and TP53 mutations were identified in 
all but 2 cases [27]. CDH1, FANCD2, CHECK2, ADH1B, 
GPC3, TP53, and PTEN genes were altered in PDCs, 
and ATM, HNF1A, MET, NF1, TP53, PTEN, MSH2, RB1, 
NBN, NF1, MUTYH, TSC2, HRAS, and EGFR genes were 
altered in ACs [27]. However, the study could not assess 
mutation of larger genes or chromosomal rearrange-
ments in a panel of 94 known cancer genes, nor could 
it distinguish germline mutations among the detected 
genetic changes.
Landa et al. performed NGS using the MSK-IMPACT 
cancer exome panel, and analyzed 341 genes from FFPE 
(N =  80) or fresh-frozen tissue (N =  37) samples from 
34 PDCs and 33 ACs [28]. The analysis revealed the fol-
lowing: (1) ACs showed a higher mutation number than 
PDCs (6 ± 5 vs. 2 ± 3, median ± interquartile range), and 
harbored a higher frequency of mutation in TP35, TERT 
promoter, PI3 K/AKT/mTOR pathway effector, SWI/SNF 
subunit, and histone methyltransferase. (2) In PDCs, clin-
icopathologic features were different based on the genetic 
alterations: 92% of RAS mutations were found in PDCs 
met the Turin criteria, whereas 81% of BRAF mutations 
were found in PDCs met the Memorial Sloan-Kettering 
Cancer Center (MSKCC) criteria. PDCs harboring BRAF 
mutations were smaller and had frequent nodal metas-
tasis, whereas RAS-mutant PDCs showed larger tumor 
sizes and a higher rate of distant metastasis. (3) The asso-
ciation of mutation between EIF1AX and RAS was nota-
ble in both PDCs and ACs. EIF1AX mutations have been 
reported in approximately 1% of PTCs, and known to be 
mutually exclusive for BRAF and RAS mutations. How-
ever, EIF1AX mutations were found in 11% of PDCs and 
9% of ACs, and 93% were associated with RAS mutations. 
(4) Chromosomal rearrangements (including RET/PTC, 
ALK, and PAX8-PPARG fusions) were found in 14% of 
PDCs, but were absent in ACs.
Medullary carcinoma
Medullary carcinoma (MC) is a neuroendocrine tumor 
originating from C-cells, and accounts for approximately 
5% of total thyroid cancers [29]. MC is composed of 75% 
sporadic form and 25% hereditary form, the latter result-
ing from a RET proto-oncogene mutation [30, 31].
Nikiforova et  al. analyzed 12 genes and 34 ampli-
cons using the ThyroSeq panel on the Ion Torrent PGM 
sequencer with FFPE or fresh frozen tissue samples from 
15 sporadic MCs. Mutations were identified in 11 (73%) 
MCs, of which 7 (47%) were RET mutations, 3 (20%) were 
HRAS mutations, and 1 (7%) was a KRAS mutation [10]. 
Simbolo et  al. analyzed 50 cancer-related genes using 
the Ion AmpliSeq Hot Spot Cancer Panel v2 on the Ion 
Torrent PGM sequencer. Out of 20 retrospectively col-
lected FFPE samples of MCs, the study found that 85% 
of MCs harbored mutations as follows: 13 RET mutations 
(60%), 3 HRAS mutations (15%), 1 KRAS mutation (5%), 
1 STK11 mutation (5%), and 3 samples where mutations 
were undetected (15%) [32]. RET status was evaluated 
with both the NGS and Sanger sequencing methods, and 
NGS showed higher sensitivity than the Sanger method. 
NGS identified an additional 3 RET mutations, which 
were undetected by the Sanger method. Although mul-
tiple mutations were found in MCs by the NGS assay, a 
relevant therapeutic target has not been identified, and 
further investigation is required to improve the treat-
ment of MCs.
Limitation of NGS technology for thyroid cancer
One of the most profound limitations of applying 
NGS for thyroid cancer is a lack of sufficient evidence-
based framework applicable to the clinical practice. As 
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discussed in this review, the number of existing studies 
using NGS to analyze thyroid cancer stands at less than 
15. Also, most of the previous studies were carried out at 
single institutes using specific subtypes of thyroid cancer 
in small sample sizes, rather than all types of thyroid can-
cers; therefore, resulting data would still be insufficient 
for making decisions on either patient diagnosis or treat-
ment in clinical practice. To overcome such limitations, 
a large-scaled, global, and multicentered NGS study for 
thyroid cancer is required.
In a thyroid nodule with indeterminate cytology and 
BRAF V600E detected by NGS, surgical resection would 
be the most appropriate treatment option, since BRAF 
V600E is a highly specific mutation for PTC [13]. In con-
trast, RAS mutation can be detected in FVPTC and fol-
licular neoplasm that require surgical excision, while 
also being present in benign adenomatous nodules [33] 
that do not require excision; therefore, further studies to 
identify the optimal treatment plan specific to mutation 
is needed. Apart from mutational variant, inadequate 
sample preparation, of both poor quality and quantity, 
can lead to false negative results. In samples with low 
tumor purity and small amount of DNA, low coverage 
would not be able to detect in allele with low frequency. 
Although DNA quality of cytology specimen is better 
than that of FFPE tissue, cytology specimens would con-
tain some amount of normal tissue component. Also, 
evaluation of tumor purity may be an essential step 
before DNA preparation, particularly if the target nodule 
is small or an inexperienced person performs the aspira-
tion procedure.
In addition to well-known BRAF, RAS, and RET muta-
tions, NGS technology facilitated detection of new 
somatic alterations in thyroid cancer such as MITF, 
MDM2, JAK3, FLI1, IDH1 etc. [20], all in which the sig-
nificance of thyroid cancer has not been delineated  yet. 
Larger scales of integrated genomic and phenotypic 
database should be provided to interpret NGS results. 
Also, an appropriate reporting system for NGS results 
in thyroid cancer is needed. Results from NGS analysis 
may encompass multiple variants, and each variant may 
have different clinical and biological significance. An 
appropriate tier system, with specific level of evidence, is 
required for reporting NGS results. Working group with 
large expertise to build a consensus guideline for report-
ing NGS results in thyroid cancer is requested. Besides 
intrinsic limitation of NGS platform, such as low detec-
tion rate of large indels, annotation errors of pipeline can 
be present. Clinicopathologic correlation and additional 
knowledge-based review of NGS report are essential for 
result interpretations. Currently, agents specifically tar-
geting defined mutations are available, and patients who 
have the targetable mutation can benefit from optimized 
treatment and avoid unnecessary therapy. Inclusion of 
potential therapeutic target genes in the gene panel of 
targeted NGS, as well as the accumulation of information 
to build up database for future investigation, would also 
be required.
Most of NGS panels applied in thyroid cancer stud-
ies cover hotspot mutations, and are highly sensitive for 
evaluation of limited regions of selected genes; however, 
relevant mutation could be missing if not appropriately 
mapped. As described in previous studies, targeted 
NGS with specific gene panel showed high PPV. How-
ever, NGS analysis using 7-gene panel in previous study 
showed that 30–35% of thyroid cancer patients were 
still negative for mutation, and low NPV would require 
diagnostic surgery in benign nodules to prevent missing 
cancers [34]. High sensitivity of NGS technique showed 
that subclones within a nodule with mutations lead-
ing to aggressive clinical behaviors might be detected 
with low allele frequency [35]. Clinicians would face a 
dilemma with such cases, regarding whether to follow up 
with their patients or to refer them to surgical resection. 
Although different platforms and variant-calling pipe-
lines were proven to have high concordance and sensitiv-
ity, detected mutations would be different in cases with 
tumor heterogeneity [36]. Genetic alteration of tumor 
results in tumor heterogeneity, which can be divided into 
intertumor heterogeneity that shows different genetic 
alterations based on the tumor sites, and intratumor 
heterogeneity that contains different genetic alterations 
within a same tumor. Concepts of aggressive clone and 
tumor heterogeneity are also present in thyroid cancer 
[37–39]. Furthermore, complicated situations may derive 
from NGS results, depending on whether NGS for each 
tissue sample was performed at relevant site and relevant 
time, and this can lead to repeated aspiration and/or 
biopsy. Also, in metastatic cancer, tissue samples should 
be obtained from metastatic sites; however, sites such as 
the brain or a specific bone are challenging for proper tis-
sue sampling.
Future of NGS for thyroid cancer
The fast-evolving NGS technology offers a cost-effective 
approach for cancer genomics, as well as in thyroid can-
cer. In future prospects of thyroid cancer, NGS can be 
used to detect circulating tumor cells or cell-free plasma 
DNA to identify early relapse and/or residual disease. 
Previous studies reported presence of circulating tumor 
cells or cell-free plasma DNA in thyroid cancer patients 
[40, 41], which appeared to be future candidates for 
NGS application. Furthermore, NGS can detect tumor-
specific genetic alterations, which are used in follow-ups 
for patient monitoring. In patient monitoring, genetic 
alterations should be present in all tumor cells, while 
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consistently and sustainably existing from both tumor 
development and during tumor progression. In thyroid 
cancer, BRAF V600E is the most common and the earliest 
genetic event in PTC [42, 43], and it appears to be a good 
candidate gene for monitoring. Also, during radioac-
tive iodine and/or drug treatment of thyroid cancer, new 
mutation variants other than primary tumor can be rec-
ognized in NGS analysis of either circulating tumor cells 
or cell-free plasma  DNA. This concept can be applied 
in identifying genetic alterations related to an acquired 
resistance to treatment during clinical course. Currently 
available studies of NGS application in thyroid cancer 
tend to focus on evaluating genetic alterations in specific 
types of thyroid cancer. In future research, an improved 
high-throughput pipeline should be used for a more 
comprehensive analysis of gene expression and DNA 
binding activity. In addition, a systems biology approach 
would also help discover the interaction and casual rela-
tionship between genes and/or proteins, introducing a 
new ground of thyroid cancer biology.
Conclusions
The emergence of NGS technology has provided in-
depth analysis of multiple, diverse cancers by a number 
of devices and gene panels, and has led to more effec-
tive options for cancer screening, prevention, diagnosis, 
prognosis, and targeted therapy. The use of NGS to study 
thyroid cancer has improved our understanding of the 
molecular genetics of thyroid cancer. In thyroid nodules 
of indeterminate cytology, such as FN/SFN and AUS/
FLUS, the NGS test detected multiple genetic alterations 
and identified patients with a high risk of malignancy. 
Risk stratification using molecular signatures offers 
many more precise treatment options during patient 
management. The application of NGS for PTC, FC, MC, 
PDC, and AC revealed novel genetic alterations which 
were not detected by past sequencing methods. Newly 
discovered genetic alterations include genes associated 
with tumor recurrence and distant metastasis, which are 
candidates for molecular prognostic markers. However, 
limitations are also present with NGS, arising from vari-
able sample types, multiple platforms and gene panels, 
and variable analysis programs, each of which can con-
found results. Standardization for quality control and 
the data-analytic process is needed to minimize the dis-
crepancies between analyses. For poor-prognostic histo-
logic types of thyroid cancer—MC, PDC, and AC—NGS 
studies identified several novel genetic alterations, but 
drug-actionable target genes have not been identified 
yet, and further investigation is required. Neverthe-
less, development of new sequencing technologies, such 
as NGS, enhances the cancer genome body of knowl-
edge, and allows for more effective cancer screening, 
prevention, diagnosis, and monitoring. This in turn pro-
vides for better precision medicine and more curative 
cancer treatments.
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